13:25:17 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-13 Kvartalsrapport 2024-Q3
2024-08-14 Kvartalsrapport 2024-Q2
2024-05-30 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2024-05-29 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-04-05 Extra Bolagsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-12-20 Extra Bolagsstämma 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-07-24 Kvartalsrapport 2023-Q2
2023-05-29 Årsstämma 2023
2023-05-16 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2023-05-08 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-16 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2022-05-13 Kvartalsrapport 2022-Q1
2022-05-13 Årsstämma 2022
2022-04-08 Extra Bolagsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2021-05-07 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-05 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2020-06-04 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-12-19 Extra Bolagsstämma 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-13 Kvartalsrapport 2019-Q2
2019-05-09 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2019-05-08 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-12 Bokslutskommuniké 2018
2018-11-20 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-07-25 Extra Bolagsstämma 2018
2018-05-09 X-dag ordinarie utdelning SIMRIS B 0.00 SEK
2018-05-08 Kvartalsrapport 2018-Q1
2018-05-08 Årsstämma 2018
2018-02-20 Bokslutskommuniké 2017
2017-11-21 Kvartalsrapport 2017-Q3
2017-08-22 Kvartalsrapport 2017-Q2
2017-05-11 Kvartalsrapport 2017-Q1
2017-05-11 Årsstämma 2017
2017-04-22 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-09-21 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHandel & varor
IndustriDagligvaror
Simris Group är ett bioteknikbolag. Bolaget är inriktat mot forskning och utveckling samt tillverkning av bioaktiva ämnen från odlade mikroalger, för tillämpningar inom nutrition, cosmeceuticals och läkemedel. Bolagets teknik ersätter även ohållbara råvaror från hotade arter och känsliga marina ekosystem. Första produkten är omega-3-tillskott som säljs under eget varumärke. Simris Group grundades 2011 och har sitt huvudkontor i Hammenhög.
2024-03-06 09:02:00

The Simris Board of Directors have resolved to temporarily pause production operations at its microalgae facility in Hammenhög, Sweden. It is clear that the optimisation of the facility for profitable production at increased scale will require between €600k and €800k of capital expenditure and the company needs time to properly determine the design, lighting, and other equipment needed to grow highly specialised biomass for new and existing customers. Simris management has therefore confirmed that it will temporarily pause biomass production at its Hammenhög manufacturing facility. The company’s intention is to resume operations once the feasibility study is completed, strategy agreed, customers secured, and funding and other support in place. This pause in Hammenhög operations is made to ensure that all cash resources are focused on the Simris Biologics business, where the Company is seeing encouraging progress in commercial discussions and in the further development of the science - not only within the ADC field, but also beyond this into other pharma applications and cosmetics.

Simris’ staff at its Hammenhög operations were informed of this decision at the time of this press release. Simris will now engage in consultation with unions that represent its staff.

Simris Group Chairman, Steven Schapera commented, Simris was founded on innovation, solving problems in a different way. This thinking is embedded in our DNA, and this review of Hammenhög operations gives us time to once again be innovative in our thinking. Simris Hammenhög must be profitable and contribute positively to the Group, the turnaround of which is now well underway. The vast potential that lies within Simris Biologics, our 2022 acquisition in the pharma space, is soon to be commercialised and we must not be distracted from that objective. This pause in operations at Hammenhög enables Management to gather all the necessary feasibility information, continue discussions with Capex investors interested in a more sustainable approach to production, and finally to make a fully-informed decision that creates wealth for Simris shareholders.”